查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087431

呼吸道感染疾病治療市場：依感染疾病類型、病原體類型、治療類型、給藥途徑、病患類型、最終使用者和通路分類－2026-2032年全球市場預測

Respiratory Tract Infection Therapeutic Market by Infection Type, Pathogen Type, Therapeutic Type, Route Of Administration, Patient Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，呼吸道感染疾病治療市場規模將成長至 893.4 億美元，複合年成長率為 8.20%。

主要市場統計數據
基準年 2025 514.5億美元
預計年份：2026年 547.4億美元
預測年份 2032 893.4億美元
複合年成長率 (%) 8.20%

急性呼吸道感染疾病仍然是重要的醫療保健領域，因為它們仍然是全球發病率、住院率、抗生素使用率和死亡率的主要原因之一。世界衛生組織（世衛組織）將下呼吸道感染疾病列為全球感染疾病感染疾病的主要原因之一，而流感、呼吸道合胞病毒（RSV）、新冠肺炎（COVID-19）、細菌性肺炎、鼻竇炎、支氣管炎以及慢性呼吸系統疾病的急性加重，持續影響住院和門診的處方趨勢。

人口老化、免疫力缺乏患者數量不斷增加、都市區空氣污染、抗生素抗藥性以及能夠區分病毒、細菌和非典型病原體的分子診斷技術的日益普及，共同推動了市場需求。競爭格局正朝著靶向抗病毒藥物、新一代抗生素、單株抗體、宿主導向療法以及循證合理使用抗生素的方向發展，而臨床差異化和療效與支付方需求的契合度是市場成功的關鍵。

治療領域的變革性變化

呼吸道感染疾病的治療模式正從廣泛的經驗性治療轉向針對特異性病原體和風險分層的治療。快速PCR檢測、床邊檢測、抗原檢測和基因組監測的改善降低了診斷的不確定性，並有助於更合理地使用抗病毒藥物和抗生素。鑑於美國疾病管制與預防中心（CDC）和世界衛生組織（WHO）持續將抗生素抗藥性列為重大的公共衛生威脅，且呼吸道感染疾病是抗生素處方的常見原因，這種轉變尤其重要。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改進標靶識別、化合物篩檢、患者分層和臨床試驗患者招募，對整個呼吸道感染疾病治療領域產生了累積影響。 AI 驅動的建模可以分析基因組數據、流行病學數據、影像數據和電子健康記錄數據，以識別新的變異、預測疾病嚴重程度並支持快速篩選候選治療方案。

關鍵區域洞察

亞太地區人口眾多，呼吸道感染疾病負擔沉重，都市區密集，且醫療保健服務覆蓋範圍不斷擴大，因此該地區被列為重點關注區域。儘管中國、印度、日本、韓國和澳洲正在加強診斷和本土製藥能力，但季節性流感、肺炎和結核病的重疊流行、空氣污染以及疫情後呼吸道疾病監測等因素，仍持續影響著治療需求。

關鍵群體特定見解

東協市場正受益於全民健康覆蓋（UHC）的擴大、私人醫療保健投資的增加以及新冠疫情後感染疾病監測的加強。市場需求集中在價格適中的抗生素、流感治療藥物和住院肺炎治療方面，而新加坡、馬來西亞、泰國、印尼、越南和菲律賓的診斷和報銷成熟度則存在差異。

主要國家的概況

美國感染疾病感染疾病基礎設施，是拉丁美洲市場潛力最大的國家。

為行業領導者提供的實用建議

產業領導者應優先研發差異化療法，以滿足明確的未滿足需求，例如重症呼吸道合胞病毒感染疾病、流感併發症、高風險患者的 COVID-19、抗藥性細菌性肺炎以及免疫力缺乏患者的呼吸道感染疾病。研發策略應結合病原體特異性療效、在易感人群中的安全性、抗藥性監測以及有助於提高用藥依從性和最佳化醫院工作流程的可操作給藥方案。

調查方法

呼吸道感染疾病治療方案的評估是透過三角測量法、專家檢驗、監管審查和競爭情報分析等二次調查進行的。二級資訊來源包括世界衛生組織（WHO）、美國疾病管制與預防中心（CDC）、美國食品藥物管理局（FDA）、歐洲藥品管理局（EMA）、歐洲疾病預防控制中心（ECDC）、各國衛生機構、同行評審期刊、臨床試驗註冊庫、公共採購文件、治療指南和藥物警戒資源。

結論

呼吸道感染疾病治療市場正朝著更精準、數據驅動和合理用藥的方向發展。這一市場的發展受到許多因素的影響，包括持續存在的疾病負擔、人口老化、抗生素抗藥性、季節性疫情爆發、空氣污染、醫療保健系統的發展，以及後新冠疫情時代對呼吸道監測的持續投入。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 呼吸道感染疾病治療市場：依感染類型分類

  • 下呼吸道感染疾病
    • 肺炎
    • 支氣管炎
    • 細支氣管炎
    • 結核
  • 上呼吸道感染疾病
    • 寒冷的
    • 鼻竇炎
    • 咽頭炎
    • 喉炎

第8章 呼吸道感染疾病治療市場：依病原體類型分類

  • 細菌感染疾病
    • 肺炎球菌
    • 流感嗜血桿菌
    • 黴漿菌支原體
  • 性行為感染
    • 流感病毒
    • 呼吸道融合細胞病毒（RSV）
    • 腺病毒
    • 新冠病毒
  • 黴菌感染疾病
    • 麴菌
    • 吉氏肺孢子蟲

第9章 呼吸道感染疾病治療市場：依治療方法分類

  • 抗生素
    • 青黴素類
    • 頭孢菌素
    • 大環內酯類
    • Fluoroquinolones抗生素
  • 抗病毒藥物
    • 神經氨酸酶抑制劑
    • 聚合酵素抑制劑
    • 單株抗體
  • 症狀治療
  • 支氣管擴張劑
  • 免疫療法

第10章 呼吸道感染疾病治療藥物市場：依給藥途徑分類

  • 口服
    • 膠囊
    • 藥片
    • 糖漿
  • 腸外
    • 靜脈
    • 肌肉內部
    • 皮下

第11章 呼吸道感染疾病治療市場：依患者類型分類

  • 成人
  • 老年人
  • 兒童

第12章 呼吸道感染疾病治療市場：依最終使用者分類

  • 醫院
  • 專科診所
  • 門診手術中心
  • 居家照護環境

第13章 呼吸道感染疾病治療市場：依通路分類

  • 線上
  • 離線

第14章 呼吸道感染疾病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 呼吸道感染疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 呼吸道感染疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Abbott Laboratories
  • Alkem Laboratories Limited
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Limited
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Steris Healthcare Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-035AB9C0DAC8

The Respiratory Tract Infection Therapeutic Market is projected to grow by USD 89.34 billion at a CAGR of 8.20% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 51.45 billion
Estimated Year [2026] USD 54.74 billion
Forecast Year [2032] USD 89.34 billion
CAGR (%) 8.20%

Respiratory tract infection therapeutics remain a critical healthcare segment because acute respiratory infections continue to account for substantial morbidity, hospitalization, antibiotic use, and mortality worldwide. The World Health Organization identifies lower respiratory infections among the leading infectious causes of death globally, while influenza, RSV, COVID-19, bacterial pneumonia, sinusitis, bronchitis, and acute exacerbations of chronic airway disease continue to shape prescribing behavior across inpatient and outpatient care.

Demand is being reinforced by aging populations, immunocompromised patient growth, urban air pollution, antimicrobial resistance, and higher use of molecular diagnostics that can distinguish viral, bacterial, and atypical pathogens. The competitive landscape is shifting toward targeted antivirals, next-generation antibiotics, monoclonal antibodies, host-directed therapies, and evidence-based antimicrobial stewardship, making clinical differentiation and payer-aligned outcomes central to market success.

Transformative Shifts in the Therapeutics Landscape

The respiratory tract infection therapeutics landscape is moving from broad empiric treatment toward pathogen-specific, risk-stratified care. Rapid PCR panels, point-of-care testing, antigen testing, and improved genomic surveillance are reducing diagnostic uncertainty and supporting more precise use of antivirals and antibiotics. This transition is especially important as the CDC and WHO continue to identify antimicrobial resistance as a major public health threat, with respiratory infections representing a frequent driver of antibiotic prescribing.

Therapeutic innovation is also being shaped by lessons from COVID-19, where accelerated trials, decentralized monitoring, platform studies, and adaptive regulatory pathways demonstrated how quickly respiratory medicines can move from discovery to deployment when public health urgency is high. The result is a more integrated model in which diagnostics, therapeutics, real-world evidence, pharmacovigilance, and stewardship programs increasingly determine clinical adoption and commercial value.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative impact across respiratory tract infection therapeutics by improving target identification, compound screening, patient stratification, and trial enrollment. AI-enabled modeling can analyze genomic, epidemiological, imaging, and electronic health record data to identify emerging variants, predict disease severity, and support faster selection of therapeutic candidates.

In commercial and clinical operations, AI is strengthening demand planning, antimicrobial stewardship, and pharmacovigilance. Hospitals and payers can use predictive analytics to reduce unnecessary antibiotic use, while manufacturers can use machine learning to monitor safety signals, identify treatment-response patterns, and optimize real-world evidence generation. These capabilities are especially relevant in influenza, RSV, COVID-19, and drug-resistant bacterial pneumonia, where timely intervention directly affects outcomes.

Key Regional Insights

Asia-Pacific is a high-priority region due to its large population base, high respiratory infection burden, dense urban centers, and expanding healthcare access. China, India, Japan, South Korea, and Australia are strengthening diagnostic capacity and domestic pharmaceutical capabilities, while seasonal influenza, pneumonia, tuberculosis overlap, air pollution exposure, and post-pandemic respiratory surveillance continue to influence therapeutic demand.

North America remains a leading region for advanced respiratory tract infection therapeutics, supported by established regulatory pathways, high diagnostic adoption, strong hospital infrastructure, immunization programs, and reimbursement for innovative medicines. Latin America is expanding access to antivirals and antibiotics, although affordability, fragmented procurement, and uneven diagnostic capacity continue to influence uptake across Brazil, Mexico, and other major markets.

Europe benefits from coordinated public health guidance, robust antimicrobial stewardship, and centralized regulatory oversight, with Germany, France, Italy, Spain, and the United Kingdom driving demand for evidence-based respiratory infection care. The Middle East is investing in hospital modernization and infectious disease preparedness, particularly across Gulf economies, while Africa faces the dual challenge of high pneumonia burden and limited access to diagnostics, oxygen, antibiotics, and newer therapeutics.

Key Group Insights

ASEAN markets are benefiting from expanding universal health coverage, rising private healthcare investment, and stronger infectious disease surveillance after COVID-19. Demand is concentrated around affordable antibiotics, influenza treatments, and hospital-based pneumonia care, with Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines showing different levels of diagnostic and reimbursement maturity.

The GCC is advancing hospital infrastructure, specialty care, and health security programs, creating opportunities for premium antivirals, injectable antibiotics, and rapid diagnostics-linked treatment pathways. The European Union continues to prioritize antimicrobial resistance containment, joint health preparedness, and evidence-based prescribing, which favors therapies with clear clinical value, safety evidence, and stewardship compatibility.

BRICS countries represent a major volume opportunity due to large patient populations, high respiratory disease burden, and expanding domestic pharmaceutical production. G7 countries lead adoption of innovative respiratory therapeutics through strong regulatory science, payer scrutiny, guideline-based care, and high use of clinical evidence. NATO member markets, while not a healthcare bloc, share strategic emphasis on medical readiness, supply chain resilience, and preparedness for respiratory outbreaks that can affect workforce continuity, emergency response, and defense readiness.

Key Country Insights

The United States leads innovation in respiratory tract infection therapeutics through strong biomedical research activity, established regulatory pathways, and high utilization of advanced diagnostics. Canada emphasizes guideline-driven care, immunization, and stewardship, while Mexico balances growing healthcare demand with access and affordability considerations. Brazil is the largest Latin American opportunity, supported by population scale, public procurement systems, and infectious disease infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature markets where payer evidence, antimicrobial stewardship, national treatment guidelines, and hospital protocols shape adoption. Russia maintains demand across antibiotics and hospital infection care, although market access can be affected by geopolitical, regulatory, and supply chain constraints.

China and India are central to global demand because of population scale, domestic manufacturing, and high respiratory infection incidence. Japan favors clinically proven, high-quality therapeutics in an aging society, while South Korea combines advanced diagnostics with strong hospital systems and rapid technology adoption. Australia maintains high standards for prescribing, surveillance, and reimbursement, supporting targeted adoption of therapeutics with demonstrated outcome benefits.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated therapies that address clearly defined unmet needs such as severe RSV disease, influenza complications, COVID-19 in high-risk patients, drug-resistant bacterial pneumonia, and respiratory infections in immunocompromised populations. Development strategies should combine pathogen-specific efficacy, safety in vulnerable groups, resistance monitoring, and practical dosing advantages that support adherence and hospital workflow.

Commercial teams should align launches with rapid diagnostics, antimicrobial stewardship, real-world evidence, and payer outcomes. Partnerships with hospitals, diagnostic providers, public health agencies, and regional distributors can improve treatment access while supporting responsible use. Supply chain resilience should be treated as a strategic requirement, especially for antibiotics, antivirals, monoclonal antibodies, and critical care injectables.

Research Methodology

The respiratory tract infection therapeutics assessment is developed through triangulated secondary research, primary expert validation, regulatory review, and competitive intelligence. Secondary sources include WHO, CDC, FDA, EMA, ECDC, national health agencies, peer-reviewed journals, clinical trial registries, public procurement references, treatment guidelines, and pharmacovigilance resources.

The methodology combines epidemiology, disease burden analysis, treatment guideline review, pipeline assessment, pricing and reimbursement evaluation, regulatory pathway analysis, and regional access assessment. Insights are validated through cross-source comparison to minimize bias and ensure that conclusions reflect verifiable clinical, regulatory, epidemiological, and commercial evidence without relying on unsupported assumptions.

Conclusion

Respiratory tract infection therapeutics are entering a more precise, data-enabled, and stewardship-driven phase. The market is shaped by persistent disease burden, aging demographics, antimicrobial resistance, seasonal outbreaks, air pollution, healthcare preparedness, and continued investment in respiratory surveillance after the COVID-19 pandemic.

Organizations that integrate diagnostic-linked treatment, AI-enabled development, robust evidence generation, responsible antimicrobial use, and resilient access strategies will be best positioned to create value. The next phase of growth will favor therapies that improve outcomes, reduce inappropriate antimicrobial use, and address the needs of high-risk patient populations across diverse healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Respiratory Tract Infection Therapeutic Market, by Infection Type

  • 7.1. Lower Respiratory Tract Infection
    • 7.1.1. Pneumonia
    • 7.1.2. Bronchitis
    • 7.1.3. Bronchiolitis
    • 7.1.4. Tuberculosis
  • 7.2. Upper Respiratory Tract Infection
    • 7.2.1. Common Cold
    • 7.2.2. Sinusitis
    • 7.2.3. Pharyngitis
    • 7.2.4. Laryngitis

8. Respiratory Tract Infection Therapeutic Market, by Pathogen Type

  • 8.1. Bacterial Infections
    • 8.1.1. Streptococcus pneumoniae
    • 8.1.2. Haemophilus influenzae
    • 8.1.3. Mycoplasma pneumoniae
  • 8.2. Viral Infections
    • 8.2.1. Influenza virus
    • 8.2.2. Respiratory Syncytial Virus (RSV)
    • 8.2.3. Adenovirus
    • 8.2.4. Coronavirus
  • 8.3. Fungal Infections
    • 8.3.1. Aspergillus
    • 8.3.2. Pneumocystis jirovecii

9. Respiratory Tract Infection Therapeutic Market, by Therapeutic Type

  • 9.1. Antibiotics
    • 9.1.1. Penicillins
    • 9.1.2. Cephalosporins
    • 9.1.3. Macrolides
    • 9.1.4. Fluoroquinolones
  • 9.2. Antivirals
    • 9.2.1. Neuraminidase Inhibitors
    • 9.2.2. Polymerase Inhibitors
    • 9.2.3. Monoclonal Antibodies
  • 9.3. Symptomatic Treatments
  • 9.4. Bronchodilators
  • 9.5. Immunotherapies

10. Respiratory Tract Infection Therapeutic Market, by Route Of Administration

  • 10.1. Oral
    • 10.1.1. Capsules
    • 10.1.2. Tablets
    • 10.1.3. Syrups
  • 10.2. Parenteral
    • 10.2.1. Intravenous
    • 10.2.2. Intramuscular
    • 10.2.3. Subcutaneous

11. Respiratory Tract Infection Therapeutic Market, by Patient Type

  • 11.1. Adults
  • 11.2. Geriatrics
  • 11.3. Pediatrics

12. Respiratory Tract Infection Therapeutic Market, by End User

  • 12.1. Hospitals
  • 12.2. Specialty Clinics
  • 12.3. Ambulatory Surgical Centers
  • 12.4. Homecare Settings

13. Respiratory Tract Infection Therapeutic Market, by Distribution Channel

  • 13.1. Online
  • 13.2. Offline

14. Respiratory Tract Infection Therapeutic Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Respiratory Tract Infection Therapeutic Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Respiratory Tract Infection Therapeutic Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Abbott Laboratories
  • 18.2. Alkem Laboratories Limited
  • 18.3. AstraZeneca PLC
  • 18.4. Boehringer Ingelheim GmbH
  • 18.5. Cadila Healthcare Limited
  • 18.6. Cipla Limited
  • 18.7. F. Hoffmann-La Roche AG
  • 18.8. GlaxoSmithKline plc
  • 18.9. Glenmark Pharmaceuticals Limited
  • 18.10. Hikma Pharmaceuticals PLC
  • 18.11. Intas Pharmaceuticals Limited
  • 18.12. Lupin Limited
  • 18.13. Merck & Co., Inc.
  • 18.14. Mylan Inc. by Viatris Inc.
  • 18.15. Novartis International AG
  • 18.16. Pfizer Inc.
  • 18.17. Sanofi S.A.
  • 18.18. Steris Healthcare Pvt. Ltd.
  • 18.19. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LOWER RESPIRATORY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LOWER RESPIRATORY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LOWER RESPIRATORY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMONIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMONIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIOLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIOLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIOLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UPPER RESPIRATORY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UPPER RESPIRATORY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UPPER RESPIRATORY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMMON COLD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMMON COLD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMMON COLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SINUSITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SINUSITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SINUSITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARYNGITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARYNGITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARYNGITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LARYNGITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LARYNGITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LARYNGITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STREPTOCOCCUS PNEUMONIAE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STREPTOCOCCUS PNEUMONIAE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STREPTOCOCCUS PNEUMONIAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HAEMOPHILUS INFLUENZAE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HAEMOPHILUS INFLUENZAE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HAEMOPHILUS INFLUENZAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MYCOPLASMA PNEUMONIAE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MYCOPLASMA PNEUMONIAE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MYCOPLASMA PNEUMONIAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADENOVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADENOVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADENOVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CORONAVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CORONAVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CORONAVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ASPERGILLUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASPERGILLUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ASPERGILLUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMOCYSTIS JIROVECII MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMOCYSTIS JIROVECII MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMOCYSTIS JIROVECII MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEURAMINIDASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEURAMINIDASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEURAMINIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNOTHERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNOTHERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNOTHERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SYRUPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SYRUPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SYRUPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 286. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 287. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 290. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 296. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 297. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS RESPIRATORY TRACT